Ascendis Pharma price target raised to $246 from $242 at BofA

BofA raised the firm’s price target on Ascendis Pharma (ASND) to $246 from $242 and keeps a Buy rating on the shares after the company announced preliminary FY25 Yorvipath sales in-line with Street estimates. Yorvipath demand trends remained strong to close the year, says the analyst, who adds that a strong Yorvipath launch “continues to be pivotal to our investment thesis.”